Related references
Note: Only part of the references are listed.Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma
Parameswaran Nair et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
The Importance of Intestinal Eotaxin-1 in Inflammatory Bowel Disease: New Insights and Possible Therapeutic Implications
Tomer Adar et al.
DIGESTIVE DISEASES AND SCIENCES (2016)
Safety and efficacy of an oral CCR3 antagonist in patients with asthma and eosinophilic bronchitis: a randomized, placebo-controlled clinical trial
H. Neighbour et al.
CLINICAL AND EXPERIMENTAL ALLERGY (2014)
Recent progress in the development of antagonists to the chemokine receptors CCR3 and CCR4
James Edward Pease et al.
EXPERT OPINION ON DRUG DISCOVERY (2014)
Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma
Elisabeth H. Bel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial
Ian D. Pavord et al.
LANCET (2012)
Up-regulation of CCL11 and CCL26 is associated with activated eosinophils in bullous pemphigoid
C. Guenther et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2011)
Overcoming hurdles in developing successful drugs targeting chemokine receptors
Thomas J. Schall et al.
NATURE REVIEWS IMMUNOLOGY (2011)
Recent advances on the use of the CXCR4 antagonist plerixafor (AMD3100, Mozobil™) and potential of other CXCR4 antagonists as stem cell mobilizers
Erik De Clercq
PHARMACOLOGY & THERAPEUTICS (2010)
CCR3 is a target for age-related macular degeneration diagnosis and therapy
Atsunobu Takeda et al.
NATURE (2009)
Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma
Pranabashis Haldar et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Mepolizumab for Prednisone-Dependent Asthma with Sputum Eosinophilia
Parameswaran Nair et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
A potent human anti-eotaxin1 antibody, CAT-213: Isolation by phage display and in vitro and in vivo efficacy
Sarah Main et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
Neuronal eotaxin and the effects of CCR3 antagonist on airway hyperreactivity and M2 receptor dysfunction
AD Fryer et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response
MJ Leckie et al.
LANCET (2000)
A small molecule antagonist of chemokine receptors CCR1 and CCR3 - Potent inhibition of eosinophil function and CCR3-mediated HIV-1 entry
I Sabroe et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Share Paper
